Brand Name | Status | Last Update |
---|---|---|
rinvoq | New Drug Application | 2024-04-26 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
rheumatoid arthritis | EFO_0000685 | D001172 | M06.9 |
Expiration | Code | ||
---|---|---|---|
UPADACITINIB, RINVOQ, ABBVIE | |||
2026-05-18 | I-919 | ||
2025-04-29 | I-888 | ||
2025-03-16 | I-886 | ||
2025-01-14 | I-883 | ||
2024-12-14 | I-880 | ||
2024-08-16 | NCE |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Upadacitinib, Rinvoq, Abbvie | |||
11564922 | 2038-03-09 | U-3624 | |
11607411 | 2038-03-09 | U-3341 | |
9951080 | 2036-10-17 | DS, DP | |
9963459 | 2036-10-17 | DP | |
10202393 | 2036-10-17 | DP | |
10344036 | 2036-10-17 | DP | |
10519164 | 2036-10-17 | DP | |
10550126 | 2036-10-17 | U-3298 | |
10597400 | 2036-10-17 | U-3255 | |
10730883 | 2036-10-17 | DP | |
10981923 | 2036-10-17 | DP | |
10981924 | 2036-10-17 | DP | |
10995095 | 2036-10-17 | U-3298 | |
11186584 | 2036-10-17 | DP | |
11198697 | 2036-10-17 | DP | |
11365198 | 2036-10-17 | U-3275 | |
11512092 | 2036-10-17 | U-3275, U-3371, U-3487 | |
11524964 | 2036-10-17 | U-3371 | |
11535624 | 2036-10-17 | U-3255 | |
11535625 | 2036-10-17 | U-3298 | |
11535626 | 2036-10-17 | U-3298 | |
11661425 | 2036-10-17 | DS, DP | |
11680069 | 2036-10-17 | DS, DP | |
11718627 | 2036-10-17 | DS, DP | |
11767326 | 2036-10-17 | U-3298 | |
11773105 | 2036-10-17 | DS, DP | |
11773106 | 2036-10-17 | U-3275, U-3371, U-3487 | |
11780847 | 2036-10-17 | DP | |
11780848 | 2036-10-17 | U-3371 | |
11787815 | 2036-10-17 | DP | |
11795175 | 2036-10-17 | U-3255 | |
8962629 | 2031-01-15 | DP | U-3255, U-3275, U-3341, U-3371, U-3624 |
RE47221 | 2030-12-01 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Arthritis | D001168 | HP_0001369 | M05-M14 | 1 | 6 | 12 | 1 | 11 | 30 |
Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | 1 | 12 | 1 | 12 | 27 |
Dermatitis | D003872 | HP_0011123 | L30.9 | 1 | 1 | 12 | 1 | 12 | 27 |
Eczema | D004485 | HP_0000964 | L30.9 | 1 | 1 | 12 | 1 | 11 | 26 |
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 6 | 9 | 1 | 8 | 23 |
Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | — | 2 | 1 | 4 | 7 |
Spondylarthritis | D025241 | — | — | — | 1 | 1 | 1 | 4 | 7 |
Spondylitis | D013166 | — | M46.9 | — | 1 | 1 | 1 | 4 | 7 |
Prurigo | D011536 | — | L28.2 | — | — | — | 1 | 1 | 2 |
Neurodermatitis | D009450 | — | L28.0 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 1 | 5 | — | 5 | 10 |
Colitis | D003092 | EFO_0003872 | K52.9 | — | 1 | 5 | — | 5 | 10 |
Crohn disease | D003424 | EFO_0000384 | K50 | — | 2 | 4 | — | 4 | 10 |
Ulcer | D014456 | MPATH_579 | — | — | 1 | 5 | — | 4 | 9 |
Systemic lupus erythematosus | D008180 | HP_0002725 | M32 | — | 2 | 1 | — | — | 3 |
Rheumatic diseases | D012216 | — | M79.0 | — | — | 3 | — | — | 3 |
Hidradenitis suppurativa | D017497 | — | L73.2 | — | 1 | 1 | — | — | 2 |
Hidradenitis | D016575 | — | — | — | 1 | 1 | — | — | 2 |
Axial spondyloarthritis | D000089183 | — | — | — | — | 1 | — | 1 | 2 |
Arteritis | D001167 | EFO_0009011 | I77.6 | — | — | 2 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | 1 | — | — | 2 | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Psoriasis | D011565 | EFO_0000676 | L40 | — | — | — | — | 1 | 1 |
Drug common name | Upadacitinib |
INN | upadacitinib |
Description | Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis. Upadacitinib is a Janus kinase (JAK) inhibitor that works by blocking the action of enzymes called Janus kinases. These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control.
|
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors; janus kinase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12 |
PDB | — |
CAS-ID | 1310726-59-0 |
RxCUI | — |
ChEMBL ID | CHEMBL3622821 |
ChEBI ID | — |
PubChem CID | 58557659 |
DrugBank | DB15091 |
UNII ID | 4RA0KN46E0 (ChemIDplus, GSRS) |